CRI Logo
  • About
    • Impact
    • History
    • Team
    • Careers
    • Blog
    • Media Room
  • What is Immunotherapy?
    • Immunotherapy Basics
    • Treatment Types
    • Cancer Types
    • Side Effects
  • Patient Support
    • Patient Resources
    • Clinical Trials
    • Immunotherapy Stories
    • Connect with ImmunoAdvocates
  • Grants & Research Programs
    • Apply for Grants
    • Research Programs
    • Clinical Programs
    • Data Programs
    • CRI Funded Scientists
  • Get Involved
    • Ways to give
    • Fundraise
    • Events
    • Partnership
    • Contact
Donate

Immune to Cancer: The CRI Blog

  • ASCO 2022 Recap: Cancer Immunotherapy Updates

    Since the first FDA approval in 2011 to treat cancer patients with checkpoint immunotherapy, doctors have sought…
    June 13, 2022| Arthur N. Brodsky, PhD
  • Sarcoma Awareness Month: Tackling Chordoma with Dr. Cassian Yee

    CRI-Chordoma Foundation CLIP Investigator Dr. Cassian Yee is exploring how to design cell therapies for patients with…

    July 1, 2021| Arthur N. Brodsky, PhD
  • AACR20 Day 2 Highlights: COVID-19, Adoptive Cell Therapy, and Checkpoint Immunotherapy Insights

    The second day of AACR’s annual meeting heard from experts at cancer centers in COVID-19 hotspots around…

    April 29, 2020| Arthur N. Brodsky, PhD
  • How Immunotherapy for Esophageal Cancer is Making an Impact

    Dr. Deirdre Cohen discusses recent advances in immunotherapy for esophageal cancer, including biomarkers, checkpoint inhibitors, cell-based therapies,…

    April 27, 2020| Arthur N. Brodsky, PhD
  • CICON19 Day 1 Update: Cancer Prevention and Combination Immunotherapy Strategies

    Day 1 of CICON19 explored how checkpoint immunotherapy might be improved through combination strategies as well as…

    September 25, 2019| Arthur N. Brodsky, PhD
  • ASCO19 Day 5 Update: CAR T Cells for Pleural Cancers and More Melanoma News

    The final day of ASCO19 covered CAR T cells for pleural cancers and long-term updates on several…

    June 5, 2019| Arthur N. Brodsky, PhD
  • ASCO19 Day 1 Update: Lung Cancer, Head and Neck Cancer, and the Cost of Immunotherapy

    The opening day at ASCO19 discussed various immunotherapy combinations for head and neck cancer, a bispecific antibody…

    June 1, 2019| Arthur N. Brodsky, PhD
  • Immunotherapy Combination Approved as First-Line Option for Patients with Advanced Triple-Negative Breast Cancer

    Patients with advanced triple-negative breast cancer can now receive frontline treatment with immunotherapy in combination with chemotherapy.

    March 8, 2019| Arthur N. Brodsky, PhD

Cancer Research Institute
29 Broadway, Floor 4

New York, NY  10006-3111

Facebook Icon
X icon
YouTube icon
LinkedIn icon
Instagram icon
Threads icon
  • About
    • Impact
    • History
    • Team
    • Careers
    • Blog
    • Media Room
  • What is Immunotherapy?
    • Immunotherapy Basics
    • Treatment Type
    • Cancer Type
    • Side Effects
  • Patient Support
    • Patient Resources
    • Clinical Trials
    • Immunotherapy Stories
    • Connect with ImmunoAdvocates
  • Grants & Research Programs
    • Apply for Grants
    • Research Programs
    • Clinical Programs
    • Data Programs
    • CRI Funded Scientists
  • Get Involved
    • Donate
    • Ways to give
    • Fundraise
    • Events
    • Partnership
    • Contact

Uniting for a World Immune to Cancer

  • Accessibility Statement
  • Privacy Policy
  • Terms & Conditions
  • Site Map

*Immunotherapy results may vary from patient to patient.

©2025, Cancer Research Institute